The most recent trading session ended with Astrazeneca (AZN) standing at $78.38, reflecting a -0.66% shift from the previouse trading day's closing. The stock's change was less than the S&P 500's ...
The AstraZeneca PLC ADR AZN slumped 0.66% to $78.38 Friday, on what proved to be an all-around mixed trading session for the ...
Zacks.com on MSN2d
Pharma Stock Roundup: FDA Approvals for LLY, MRK, AZN & JNJ DrugsThis week, the FDA approved Eli Lilly’s LLY eczema drug, Ebglyss (lebrikizumab), and the expanded use of Novartis’ NVS ...
AstraZeneca PLC AZN shares inched down 0.99% to £117.80 Friday, on what proved to be an all-around rough trading session for ...
In a report released today, Eric Le Berrigaud from Stifel Nicolaus maintained a Buy rating on AstraZeneca (AZN – Research Report), with a ...
Until recently, the pharmaceutical industry remained relatively insulated from the simmering trade war between China and the ...
Our writer identifies three stocks on the FTSE 100 he feels would add the variety of growth, income and stability to his own ...
When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about ...
Instead of four equal quarterly distributions, AstraZeneca insists on two payments per year, with a greater portion announced ...
AstraZeneca (AZN – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Sachin Jain ...
ArriVent BioPharma is developing a treatment for non-small cell lung cancer. Click here to read more about AVBP stock and ...
With a trio of biotechs hitting the Nasdaq on Friday, it was easy to miss a smaller-scale public debut from another ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback